

Supplementary Figures




Figure S1. Combination of mito and oHSV fails to control MC38 tumors. (A) Tumor growth kinetics and **(B)** Kaplan-Meier survival curves from mice bearing MC38 tumors treated with different combinations of mito and oHSV monotherapy and combination therapy.




Figure S2. Depletion of T cells with monoclonal antibodies. Anti-CD8 or anti-CD4 monoclonal antibodies were administered to tumor-bearing mice by i.p. Number of CD8 T cells, CD4 T cells, B cells and NK cells in circulation were assessed by flow cytometry.




Figure S3. mito + oHSV induces RNA transcriptomes associated with recruitment and activation of myeloid subsets. Mice harboring MC38 tumors were treated with different combinations of mito, oHSV and/or ICI. RNA was harvested from the tumors one day after the final treatment and sent for analysis by Clariom S assay. The heat map shows genes differentially expressed between mito + oHSV compared to PBS control.




Figure S4. Tumor infiltration of cDC2s and moDCs. Mice bearing MC38 tumors were treated with different combinations of mito, oHSV and/or ICI. Tumors were harvested 4 days after start of treatment and the frequency of infiltrating immune cells was analyzed by flow cytometry. cDC2s (CD11c⁺ MHCII⁺ CD11b⁺ Ly6C⁻) and moDCs (CD11c⁺ MHCII⁺ CD11b⁺ Ly6C⁺) were graphed.




Figure S5. T cell gating strategy. Mice bearing MC38 tumors were treated with different combinations of mito, oHSV and/or ICI. Tumors were harvested 7 days after start of treatment and the frequency of infiltrating immune cells was analyzed by flow cytometry. Cells were gated on viable CD45⁺.




Figure S6. Myeloid gating strategy. Mice bearing MC38 tumors were treated with different combinations of mito, oHSV and/or ICI. Tumors were harvested 4 days after start of treatment and the frequency of infiltrating immune cells was analyzed by flow cytometry. Cells were gated on viable CD45⁺. **(A)** Neutrophils and monocytes. **(B)** DCs.

Table S1. Differentially expressed genes associated with myeloid subset recruitment and activation. M = mito, O = oHSV, I = ICI. ns = P > 0.05.

| Gene Symbol | M + O + I vs PBS | M + O vs PBS | ICI vs PBS | oHSV vs PBS | mito Vs PBS |
|-------------|------------------|--------------|------------|-------------|-------------|
| Lcn2 | 14.18 | 11.69 | 2.52 (ns) | 16.79 | 2.03 (ns) |
| Cxcl2 | 11.77 | 23.53 | 2.36 (ns) | 8.38 | 1.96 |
| Ccl3 | 9.78 | 16.41 | 3.17 | 8.46 | 1.43 |
| Nos2 | 7.73 | 4.83 | 1.19 | 3.47 | 1.08 |
| Serpinb2 | 7.55 | 3.04 | 2.35 (ns) | 3.88 | -1.13 |
| S100a9 | 6.76 | 5.87 | 1.81 | 6.37 | 1.49 |
| S100a8 | 6.62 | 7.54 | 2.36 | 5.99 | 1.24 |
| Irg1 | 6.6 | 3.57 | 1.02 | 4.6 | 1.68 |
| Ly6c2 | 5.81 | 5.08 | 4.02 | 5.85 | 2.41 |
| Slfn4 | 5.8 | 7.46 | 1.39 | 3.33 | 2.37 |
| Sell | 5.24 | 5.23 | 2.03 | 4.85 | 2.04 (ns) |
| Ly6c1 | 4.26 | 2.66 | 3.24 | 3.43 | 1.65 |
| Il1a | 4.21 | 4.15 | 2.36 | 2.67 | -1.15 |
| Clec4d | 3.85 | 3.54 | 3.24 | 3.05 | 1.79 |
| Tarm1 | 3.69 | 1.91 | 5.02 | 1.89 | 1.69 |
| Upp1 | 2.99 | 2.08 | 3.95 | 2.47 | 2.11 |
| Il1b | 2.96 | 2.24 | 1.75 | 2.74 | -1.21 |
| Cxcl1 | 2.92 | 1.84 | 1.65 | 1.72 | -1.63 |
| Ccl7 | 2.74 | 1.88 | 1.18 | 1.9 | 1.43 |
| Ccr12 | 2.63 | 2.53 | 2.79 | 2.09 | 1 |
| Ccl5 | 2.47 | 3.11 | 1.73 | 1.34 | 2.77 |
| Cxcl10 | 2.41 | 2.18 | 3.54 | 2.16 | 1.32 |
| Cxcl5 | 2.01 | 1.38 | 1.88 | 1.69 | -1.1 |